Gilead Sciences’ Revenue Breakdown Worldwide (2016 – 2021)

Exclusive Data

You need the Pro Plan for unlimited access.

Pro Plan

$39 per month*

51% discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

Download

About

This statistic highlights Gilead Sciences’ Revenue Breakdown Worldwide from Q1 2016 onwards, split between Europe, Other International, and United States, reported on a quarterly basis.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPI Data on listed stocks for just $19/month

This statistic highlights Gilead Sciences’ Revenue Breakdown Worldwide from Q1 2016 onwards, split between Europe, Other International, and United States, reported on a quarterly basis.

Gilead Sciences, Inc. is a biopharmaceutical company that has spent more than three decades pursuing and achieving medical discoveries to make the world a healthier place for everyone. Harvoni and Sovaldi are two antiviral medicines developed by the company, which are used to treat HIV, hepatitis B, hepatitis C, and influenza. The company’s new medications reflect improvements by providing first-class therapies, increased effectiveness, improved routes of delivery, more convenient treatment regimes, improved resistance profiles, and decreased adverse effects. In addition, the company’s focus on innovation has allowed by providing marketed goods in a variety of therapeutic areas.

Gilead Sciences’ Revenue Breakdown Worldwide

Gilead Sciences, Inc. generates its revenue from the following regions:

  • Europe
  • Other International
  • United States

The following table sheds more light on each of the region and their contribution to the company’s overall top line.

Region Q1 2020 Q1 2021 YOY Growth Revenue Share in Q1 2021
Europe $927.00 $1,340.00 44.55% 20.85%
Other International $551.00 $827.00 50.09% 12.87%
United States $3,990.00 $4,260.00 6.77% 66.28%
Total $5,468.00 $6,427.00 17.54% 100.00%

(All figures in millions, except percentages)

Gilead Sciences, Inc.’s total revenue rose from $5,468 million in Q1 2020 to $6,427 million in Q1 2021, marking an increase of 17.54% on a year-on-year basis.

Gilead Sciences, Inc. generates its revenue from different segments like Viread, Truvada, Emtriva, HIV products, AmBisome, Atripla, Letairis, Ranexa, Complete Eviplera, Stribild, Sovaldi, and Harvoni. These are the products of the company.

Europe

Gilead Sciences’ revenue from the Europe region increased from $927 million in Q1 2020 to $1340 million in Q1 2021, marking an increase of 44.55% on a year-on-year basis. During this period, this region contributed 20.85% to the company’s total revenue. Gilead and the European Union have agreed to a six-month joint procurement agreement that will cover Veklury purchases until April 2021. Product sales in Europe grew by 9% in 2020, owing largely to Veklury sales and continuing patient adoption of Biktarvy and Yescarta. This is a key revenue generator for the company.

Other International

Gilead Sciences’ revenue from the Other International regions rose from $551 million in Q1 2020 to $827 million in Q1 2021, marking an increase of approximately 50% on a year-on-year basis. In Q1 2021, this region contributed 12.87% to Gilead Sciences’ total revenue. This revenue growth was primarily due to higher sales volumes of Biktarvy, Veklury, and Vemlidy. product sales in this region increased by 17%.

United States

Gilead Sciences’ revenue from the United States increased from $$3,990 million in Q1 2020 to $4,260 million in Q1 2021, marking an increase of 6.77% on a year-on-year basis. During this period, this region contributed 66.28% to the company’s total revenue.

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company established in 1987 by Michael L. Riordan. It is headquartered in Foster City, California, United States. Daniel O’Day is the current Chairman and CEO of the company. The company operates in more than 35 countries worldwide. The company faces tough competition from Vertex, Genentech, Cipla, Bristol-Myers Squibb, Biogen, Amgen, and Jazz Pharmaceuticals. Gilead Sciences is traded on the Nasdaq stock exchange in 1992 under the ticker code “GILD”.

Gilead Sciences has acquired Nexstar Pharmaceuticals, Myogen, Immunomedics, MYR GmbH, and Kite Pharma until 2020. The company has 11,800 employees worldwide.

Did you like Gilead Sciences’ Revenue Breakdown Worldwide statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
$9.9
per month*
Buy Now

51% discount until July 31

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
per month*
Buy Now

51% discount on Annual plan

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star 51% off

Get Pro for 51% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $39 $10 / month

.